|
|
||||||||
Center for Immunology and Department of Pathology, Washington University School of Medicine, St. Louis, MO 63110
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
A direct quantitation of the density of ligand required for negative selection may be very useful for understanding the natural history of autoreactive T cells. To do this, we have taken advantage of a TCR transgenic mouse specific for an epitope of hen egg white lysozyme (HEL),3 3A9 9 . First, we know the precise HEL peptide sequences displayed after processing by APCs. The processing of HEL results in the presentation of a dominant family of peptides bearing the core sequence from residues 52 to 61, which is usually displayed from residue 48 to residues 61, 62, or 63 (DGSTDYGILQINSR/W/W) 10 . In this study, we used the 4861 peptide that contains all of the MHC anchor residues for I-Ak and the TCR-contacting residues for 3A9 11 .
A second advantage relates to the peptide itself; 4861 binds with relatively high affinity to I-Ak; this complex is highly stable, with a time of persistence in APCs much longer than the average I-Ak molecule 12 . Third, we have available a mAb, AW3.18, that specifically binds to the 4861/I-Ak complexes 13 . Measuring complexes with this Ab on APCs is superior to using radioactive peptides for the following reasons: 1) the Ab recognizes the peptide in the same register as the 3A9 TCR, 2) it binds to the extracellular I-Ak on the APC, and 3) it reflects the physiological epitope presented at a given point in time.
| Materials and Methods |
|---|
|
|
|---|
The 3A9 mice used in this study were obtained from Dr. Mark Davis (Stanford University School of Medicine, Stanford, CA) 9 . They were back-crossed to B10.BR (H-2k) and maintained in the Washington University mouse facility. Mice were screened by FACS analysis of PBLs with anti-CD4 FITC (GK1.5) and biotinylated anti-V-ß8 (MR5-2; PharMingen, San Diego, CA).
Antibodies
Anti-CD4, anti-CD69, and anti-V-ß8 were purchased from PharMingen. Anti-CD8 quantum red and propidium iodide (PI) were purchased from Sigma (St. Louis, MO).
Activation determined by CD69 induction
The APCs used in these studies were M12.C3.F6 14 and murine B lymphoma cells transfected with I-Ak. These APCs were incubated for 20 h with titrating concentrations of 4861 peptide (5 x 104 in 100 µl/well in 96-well trays) and subsequently washed three times before the addition of thymocytes. Thymocytes and APCs were then incubated together for an additional 20 h. Next, cells were stained with anti-CD4 FITC, anti-CD8 quantum red, and anti-CD69 biotin, followed by Neutralite avidin-phycoerythrin (Southern Biotechnology Associates, Birmingham, AL). PI at 300 µg/ml was added to samples immediately before analysis on the FACScan (Becton Dickinson, Mountain View, CA). Lymphocytes were gated by forward and side scatter, and cells incorporating PI (dead cells) were excluded from the analysis. The geometric mean fluorescence (MF) of FL-2 (CD69) was then calculated for the CD4+CD8- T cells. The maximum CD69 up-regulation was calculated as follows: 100 x (X - min/max - min), where X is the MF for a given Ag concentration, min is the MF of T cells incubated with APCs but no Ag, and max equals the maximum MF observed.
In vitro deletion
In vitro deletion was performed as described by Iwabuchi et al.
15 , with the following modifications: APCs were prepared as described
above. Thymocytes from 68-wk-old 3A9 mice were added to the wells at
a ratio of 10 thymocytes to one APC (usually about
7.5 x
105 thymocytes/well). Thymocytes and APCs were incubated
for 20 h and then resuspended; a sample was counted by trypan blue
exclusion on a hemocytometer. The percentage of
CD4+CD8+ PI-negative thymocytes
(non-FL-3bright) was subsequently examined.
Measurement of peptide-MHC complexes per APC
The AW3.18 Ab was radioiodinated using the chloramine T method 13 . M12.C3.F6 cells were cultured in vitro at 5 x 105/ml in the presence or absence of the HEL 4861 peptide for 20 h. Cells were then washed and resuspended in HBSS media containing 1% BSA and 5 mM HEPES buffer at a concentration of 1 or 2 x 107/ml. The cells were incubated for 2 h with titrating amounts of intact labeled Ab and then centrifuged through oil to separate cell-bound and free Ab. M12.C3.F6 cells incubated without peptide were used to calculate background binding of the Ab (typically <1%). The total number of sites per cell was calculated using Scatchard analysis of the four to six different Ab input concentrations (each was done in triplicate) per experimental peptide concentration; this allowed us to determine the nanograms of Ab bound at saturation and the number of sites per cell at saturation. To extrapolate the number of peptide-MHC complexes, the data were fitted to the following formula 16, 17 as a "user-defined, nonlinear regression" with GraphPad Prism Software (GraphPad, San Diego, CA): (pep-MHC)/(MHC)total = (Ka x [pep]total)/(1 + Ka x [pep]total), where pep-MHC equals the number peptide-MHC complexes per APC, MHCtotal equals the total number of MHC molecules available for binding peptide per APC, Ka is the association constant for peptide-MHC, and [pep]total is the concentration of peptide. This formula derived the following apparent values for Ka and MHCtotal: Ka = 272,500 M-1 (SEM = 96,640), and MHCtotal = 126,000 (SEM = 22,850). Using these values in the above equation, we were able to determine the number of peptide-MHC complexes per APC at the relevant concentrations of peptide.
| Results |
|---|
|
|
|---|
50% of input thymocytes. This loss was attributable to
the deletion of DP thymocytes, because there was no significant
decrease in SP cells (Fig. 1
|
|
Fig. 2
shows the striking difference in the sensitivity between these
two responses. Although 100 pM peptide affected 50% maximum deletion,
10 nM peptide was required for a 50% maximum induction of CD69 on the
SP cells. Thus, the dose of peptide required for 50% maximum deletion
was 100-fold lower than for 50% maximum activation (Fig. 2
).
Using 125I-radiolabeled AW3.18, the number of peptide-MHC
complexes formed ranged from 70,000 to 100,000 for the highest doses of
peptide. The lowest directly measurable complexes were
5000/APC at
1 x 10-7 M peptide (Fig. 3
). These directly measured values of
peptide occupancy fit the equation (curve shown in Fig. 3
) used
previously 16, 17 to describe peptide binding to MHC molecules (i.e.,
apparent association constant and maximum number of sites per cell).
From these values, we extrapolated the number of complexes at the
peptide concentrations in which we observed deletion and activation.
The number of peptide-MHC complexes per APC for activation (10 nM) was
340 complexes (164579 at the 95% confidence interval). The number
of complexes per APC for deletion (100 pM) was only 3.4 (1.65.8 at
the 95% confidence interval).
|
| Discussion |
|---|
|
|
|---|
These very low numbers argue against extensive receptor aggregation as a requirement for this sensitive signaling process. This signal may represent an increment above the initial basal process of TCRs interacting with MHC molecules that do not contain the specific peptides, a point that has been argued previously 25, 26 . From this perspective, the entire process of a T cell response is a continuum of interactions modulated by the stage of T cell development (i.e., DP to a naive and to an effector/memory stage, the nature and amount of the ligand, and the contribution of adhesion/costimulatory molecules by the APCs). In our case, we use an APC line that contributes a strong adhesion/accessory function to the 3A9 T cell.
The very high sensitivity of the deletion process of the DP thymocytes assures that virtually any level of protein expressed in thymic APCs will eliminate the highest affinity and presumably the most dangerous autoreactive T cells. Indeed, we expect that many blood serum proteins would be represented by only a few peptides per thymic APC, when considering their levels in the blood and the thymic blood barrier as well as the competition among proteins for processing and binding to MHC molecules. Of course, the affinity of the TCR for the complex will be a component that determines the number of peptide-MHC complexes required for a given activation parameter 25, 16 . Extrapolating our results to autoreactive T cells having properties akin to the 3A9 T cells, we can argue that a gradient of self-peptide-MHC complexes is unlikely to explain positive and negative selection 6 given the limited number of complexes active in negative selection. We would argue more for positive selection to involve epitopes that are cross-reactive with the natural ligand 27 .
Our data also reveal that the self-reactive T cells in the peripheral
lymphoid tissues have a substantially higher threshold of activation.
This higher threshold is the "margin of safety" to which Yagi and
Janeway 2 referred and which we have translated into a "biochemical
margin of safety": Engaging functionally autoreactive T cells that
were not centrally purged would require a relatively high efficiency of
representation of peptide-MHC complexes on the peripheral APCs
(
0.1% occupancy of MHC molecules). APCs varying from
105 to 106 class II MHC molecules/cell would
require 0.030.3% occupancy by peptides. (The content in our APCs is
similar to dendritic cells;
106/cell.) In a
typical chemical isolation of class II bound peptides from APCs, the
number of peptides represented below the level required for triggering
T cells is considerable. In our experience, a recovery of 500 pmol of
peptide isolated from 1010 APCs would represent 0.3%
occupancy, but many peptides are identified with 100- to 100,000-fold
less abundance (picomole to femtomole levels) 28, 29, 30, 31 .
Thus, most of the self-peptides bound to MHC would not be found in sufficient quantity to drive a self-reactive T cell response. This margin of safety places the following conditions for the stimulation of autoreactive T cells: that a large pool of self-protein be present, perhaps in a suitable microenvironment; that changes in Ag presentation occur that would preferentially enhance self-Ag presentation; or that events that lower the normal threshold of activation of the T cell take place. Along these lines, activated T cells react to a lower level of peptide-MHC complexes 18, 19 , to note is the very high sensitivity of effector CD8 T cells, which can kill targets bearing a few class I MHC-peptide complexes 32 .
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Emil R. Unanue, Washington University School of Medicine, Department of Pathology, 660 S. Euclid Avenue, St. Louis, MO 63110. E-mail address: ![]()
3 Abbreviations used in this paper: HEL, hen egg white lysozyme; PI, propidium iodide; MF, mean fluorescence; SP, single positive; DP, double positive. ![]()
Received for publication December 8, 1998. Accepted for publication January 8, 1999.
| References |
|---|
|
|
|---|
1 and mitogen-activated protein kinase in naive and antigen-primed CD4 T cells by the peptide/MHC ligand. J. Immunol. 156:2045.[Abstract]
This article has been cited by other articles:
![]() |
L. M. Relland, M. K. Mishra, D. Haribhai, B. Edwards, J. Ziegelbauer, and C. B. Williams Affinity-Based Selection of Regulatory T Cells Occurs Independent of Agonist-Mediated Induction of Foxp3 Expression J. Immunol., February 1, 2009; 182(3): 1341 - 1350. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Derbinski, S. Pinto, S. Rosch, K. Hexel, and B. Kyewski Promiscuous gene expression patterns in single medullary thymic epithelial cells argue for a stochastic mechanism PNAS, January 15, 2008; 105(2): 657 - 662. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Hailman and P. M. Allen Inefficient Cell Spreading and Cytoskeletal Polarization by CD4+CD8+ Thymocytes: Regulation by the Thymic Environment J. Immunol., October 15, 2005; 175(8): 4847 - 4857. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. F. Shih, L. Mandik-Nayak, B. T. Wipke, and P. M. Allen Massive Thymic Deletion Results in Systemic Autoimmunity through Elimination of CD4+ CD25+ T Regulatory Cells J. Exp. Med., February 2, 2004; 199(3): 323 - 335. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Hill, S. Southwood, A. Sette, A. M. Jevnikar, D. A. Bell, and E. Cairns Cutting Edge: The Conversion of Arginine to Citrulline Allows for a High-Affinity Peptide Interaction with the Rheumatoid Arthritis-Associated HLA-DRB1*0401 MHC Class II Molecule J. Immunol., July 15, 2003; 171(2): 538 - 541. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Veeraswamy, M. Cella, M. Colonna, and E. R. Unanue Dendritic Cells Process and Present Antigens Across A Range of Maturation States J. Immunol., June 1, 2003; 170(11): 5367 - 5372. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Viret, X. He, and C. A. Janeway Jr. Altered positive selection due to corecognition of floppy peptide/MHC II conformers supports an integrative model of thymic selection PNAS, April 29, 2003; 100(9): 5354 - 5359. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Haribhai, D. Engle, M. Meyer, D. Donermeyer, J. M. White, and C. B. Williams A Threshold for Central T Cell Tolerance to an Inducible Serum Protein J. Immunol., March 15, 2003; 170(6): 3007 - 3014. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Viret and C. A. Janeway Jr. Self-Specific MHC Class II-Restricted CD4-CD8- T Cells That Escape Deletion and Lack Regulatory Activity J. Immunol., January 1, 2003; 170(1): 201 - 209. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Dustin and D. R. Colman Neural and Immunological Synaptic Relations Science, October 25, 2002; 298(5594): 785 - 789. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. DiPaolo and E. R. Unanue Cutting Edge: Chemical Dominance Does Not Relate to Immunodominance: Studies of the CD4+ T Cell Response to a Model Antigen J. Immunol., July 1, 2002; 169(1): 1 - 4. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. Sant'Angelo and C. A. Janeway Jr. Negative selection of thymocytes expressing the D10 TCR PNAS, May 14, 2002; 99(10): 6931 - 6936. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Chakraborty How and Why Does the Immunological Synapse Form? Physical Chemistry Meets Cell Biology Sci. Signal., March 5, 2002; 2002(122): pe10 - pe10. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Peterson, R. J. DiPaolo, O. Kanagawa, and E. R. Unanue Cutting Edge: A Single MHC Anchor Residue Alters the Conformation of a Peptide-MHC Complex Inducing T Cells That Survive Negative Selection J. Immunol., May 15, 2001; 166(10): 5874 - 5877. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Velazquez, R. DiPaolo, and E. R. Unanue Quantitation of Lysozyme Peptides Bound to Class II MHC Molecules Indicates Very Large Differences in Levels of Presentation J. Immunol., May 1, 2001; 166(9): 5488 - 5494. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Lucas and R. N. Germain Opening a Window on Thymic Positive Selection: Developmental Changes in the Influence of Cosignaling by Integrins and CD28 on Selection Events Induced by TCR Engagement J. Immunol., August 15, 2000; 165(4): 1889 - 1895. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Kersh, D. L. Engle, C. B. Williams, and P. M. Allen Ligand-Specific Selection of MHC Class II-Restricted Thymocytes in Fetal Thymic Organ Culture J. Immunol., June 1, 2000; 164(11): 5675 - 5682. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Fahlen, L. Oberg, T. Brannstrom, N. K. S. Khoo, U. Lendahl, and C. L. Sentman Ly49A expression on T cells alters T cell selection Int. Immunol., February 1, 2000; 12(2): 215 - 222. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |